Nicorandil Zydus

Nicorandil, the active ingredient in Nicorandil Zydus, is a vasodilator presented as an oral tablet for oral use. It treats chronic stable angina in adults by improving myocardial oxygen balance. GNH USA supplies Nicorandil Zydus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nicorandil is an anti‑anginal vasodilator used in the management of coronary artery disease.

- Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance. - Effort‑induced angina: provides symptomatic relief during physical activity. - Refractory angina: offers an alternative when conventional therapy is insufficient.

Nicorandil may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness. - Dizziness: especially upon standing. - Nausea: occasional gastrointestinal upset. - Palpitations: awareness of heartbeat. - Hypotension: mild blood pressure reduction.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Ulceration: gastrointestinal ulcer formation. - Stevens‑Johnson syndrome: severe skin reaction. - Anaphylaxis: life‑threatening allergic response. - Liver dysfunction: abnormal liver enzymes or hepatitis.

Before initiating therapy, consider the following precautions.

- Monitor blood pressure: watch for symptomatic hypotension. - Assess cardiac status: avoid in unstable angina or recent myocardial infarction. - Review concomitant nitrates: combined use may cause profound hypotension. - Use caution in hepatic impairment: adjust therapy if liver function is compromised. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep below 25°C, protect from moisture and keep in original packaging.

Nicorandil can interact with several drug classes.

Major Interactions (Avoid): - Concomitant nitrates: additive vasodilation leading to severe hypotension. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): risk of profound hypotension. - Other potassium channel openers: synergistic vasodilatory effect.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask tachycardia signs. - Calcium channel blockers: additive blood‑pressure lowering effect. - Diuretics: may enhance hypotensive response.